Treatment with blinatumomab given subcutaneously.
Phase 2RecruitingDevelopment Stage
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia
Mar 1, 2026 → Dec 1, 2031
About Treatment with blinatumomab given subcutaneously.
Treatment with blinatumomab given subcutaneously. is a phase 2 stage product being developed by Amgen for Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07301424. Target conditions include Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07301424 | Phase 2 | Recruiting |
Competing Products
20 competing products in Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)